International Biotechnology Trust is also unusual among more growth share-focussed investment trusts in paying a substantial dividend, with a current yield of 5.01 per cent. Ailsa joins Simon Lambert and Richard Hunter on this episode of the Investing Show to discuss biotech investing and some of the firms at the cutting edge of medicine that International Biotechnology Trust invests in. Ailsa argues that biotech is an area where armchair investors buying individual stocks can expose themselves to very high risks. There are ways to mitigate the risk of biotech investing, Ailsa says, and that is something the trust aims to do with both its medical and professional expertise and portfolio positioning. However, IBT has outperformed the sector and protected investors better over the past year, falling 11.6 per cent compared to a 18.2 per cent sector average decline.
Source: Daily Mail June 23, 2022 03:12 UTC